ESTRO 2024 - Abstract Book

S1802

Clinical - Lung

ESTRO 2024

Conclusion:

The addition of atezolizumab to chemotherapy significantly improved OS but did not affect the risk of subsequent brain metastasis in patients with extensive-stage SCLC, mirroring IMpower133 and CASPIAN trial outcomes in a real word cohort. PCI (but not thoracic RT) improved OS in extensive-stage SCLC patients treated with chemoimmunotherapy.

Keywords: SCLC, prophylactic cranial irradiation.

References: